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Background: Malaria is the most prevalent parasitic disease in the world. In Brazil, the largest number of malaria
cases (98%) is within the Legal Amazon region, where Plasmodium vivax is responsible for over 80% of diagnosed
cases. The aim of this study was to investigate the annexin-A1 expression in CD4+, CD8+ T cells, regulatory T cells
(Treg) and cytokine IL-10 quantification in plasma from patients with malaria caused by P. vivax.
Methods: The quantification of the cytokine IL-10 of patients infected with P. vivax and healthy controls were evaluated
by enzyme-linked immunosorbent assay (ELISA). The determination of the expression of annexin-A1 in lymphocytes
from patients and healthy controls was determined by immunofluorescence staining. All results were correlated with
the parasitaemia and the number of previous episodes of malaria.
Results: The cytokine IL-10 plasma levels showed a significant increase in both patients with low (650.4 ± 59.3 pg/mL)
and high (2870 ± 185.3 pg/mL) parasitaemia compared to the control (326.1 ± 40.1 pg/mL). In addition, there was
an increase of this cytokine in an episode dependent manner (individuals with no previous episodes of malaria -
primoinfected: 363.9 ± 31.1 pg/mL; individuals with prior exposure: 659.9 ± 49.4 pg/mL). The quantification of
annexin-A1 expression indicated a decrease in CD4+ and CD8+ T cells and an increase in Treg in comparison with
the control group. When annexin-A1 expression was compared according to the number of previous episodes of
malaria, patients who have been exposed more than once to the parasite was found to have higher levels of CD4+ T
cells (96.0 ± 2.5 A.U) compared to primoinfected (50.3 ± 1.7). However, this endogenous protein had higher levels in
CD8+ (108.5 ± 3.1) and Treg (87.5 ± 2.5) from patients primoinfected.
Conclusion: This study demonstrates that in the patients infected with P. vivax the release of immunoregulatory
molecules can be influenced by the parasitaemia level and the number of previous episodes of malaria. annexin-A1 is
expressed differently in lymphocyte sub-populations and may have a role in cell proliferation. Furthermore, annexin-A1
may be contributing to IL-10 release in plasma of patients with vivax malaria.
Keywords: Plasmodium vivax, Annexin-A1, Interleukin-10 (IL-10), CD4+, CD8+, TregBackground
In Brazil, the largest number of malaria cases (98%) occurs
within the Legal Amazon region. Between 2005 and 2009,
the number of cases decreases from 607,801 to 306,908.
A similar reduction was found for mortality (52.5%)
and malaria incidence (25.6 to 12.1 cases per thousand* Correspondence: asdamazo@yahoo.com.br
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reproduction in any medium, provided the orinhabitants). In 2011, only 263,323 cases were reported
[1]. In other Brazilian regions, the transmission risk is
low or nonexistent [2]. In Mato Grosso, the disease is
predominantly focal. It is endemic only in the northern
region of the State [3] with 2,161 cases reported in
2010 [4].
The infection caused by Plasmodium vivax has long been
considered a benign disease, especially when compared to
infections caused by Plasmodium falciparum [5]. Recently,
literature report has shown that vivax malaria caused more
severe forms of the disease than previously described, andLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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severe anaemia, respiratory distress and acute lung injury,
coma, among other manifestations [6,7]. The increasing
drug resistance and the complications of this parasitic
disease require joint efforts for a better understanding
and resolution.
Evidence suggests that during infection, malaria causes
activation and dysfunction of T cells and lymphopaenia [8].
The CD8+ T cells and the cytokines IFN-γ and TNF confer
protection against parasites pre-erythrocytic Plasmodium
within hepatocytes [9], whereas CD4+ T cells restricted
growth of parasites erythrocytes of Plasmodium through
secretion of cytokines, activation of macrophages and
direction of humoral immunity [10]. Recently, the involve-
ment of regulatory T cells in infection caused by P. vivax
was demonstrated [11], suggesting that the balance between
pro-and anti-inflammatory cytokines is needed to track
changes related to malaria [12].
Besides cytokines, other factors can modulate the differ-
entiation of T helper lymphocytes, for example, the affinity
of the antigen by a T cell receptor (TCR). With low affinity
antigen generally induce a Th2 response, whereas high
affinity induces differentiation into a Th1 response [13,14].
Annexin-A1 (ANXA1) is an endogenous protein with
anti-inflammatory functions, endowed with potent anti-
migratory activity of neutrophils, ensuring the transitory
nature of the inflammatory response [15,16]. This protein
is identified in several types of leukocytes [17,18] and posi-
tively modulates TCR signaling, making it an important
molecular target in the differentiation and proliferation
of lymphocytes. In the lymphocytes, ANXA1 has been
characterized as an antiproliferative protein [17], but new
studies have indicated other mechanisms, like regulates
the T cell production of IFN-γ, IL-17, TNF and IL-6
[19] and the suppressive activity of apoptotic cells on
the immune response [20].
Therefore, the aim of this study was to investigate the
expression of ANXA1 in CD4+, CD8+ T cells, regulatory
T cells (Treg) and quantification of the cytokine IL-10 in
plasma from patients with malaria caused by P. vivax.
The relationship between the presence of lymphocyte sub-
populations and release of immunoregulatory molecules
may contribute to the understanding of the dynamics of
the immune response in vivax malaria.
Methods
Malaria patients and healthy controls
Sixty-nine malaria patients from the Julio Müller University
Hospital of the Federal University of Mato Grosso State,
Cuiabá – MT, were included in this study. The age, number
of previous episodes of malaria, and other infectious
diseases history of each participant were recorded using
a standard questionnaire. Patients who have already
been treated with some type of anti-malarial drug wereexcluded from the study. Thirty-seven healthy volunteers
living in Cuiabá, a non-endemic malaria area, were
recruited as the control group. These volunteers had no
history of malaria infection. Written informed consent was
obtained from all patients or their legal representatives
before enrollment in the study. The study protocol was
approved by the Ethics Committee from Julio Müller
University Hospital (633/CEP-HUJM/09). The study
subjects were matched by sex and age. The average age
of patients with malaria was 33.7 ± 1.9 years. And it
was 37.6 ± 2.2 years in the control group.
Blood collection
Blood samples were taken from each patient. A finger-tip
smear was taken for the parasitological diagnosis, and then
approximately 5 mL of venous blood was collected for
the analysis of cytokines and ANXA1 expression. The
blood was drawn aseptically into Vacutainer® tubes (Becton
Dickson and company, Franklin Lakes, NJ, USA) with
EDTA. The haemoglobin, platelets and whole blood
cells (WBC) were quantified with the Blood Cell Count
(Pentra, Horiba Diagnostics, Kyoto, Japan). After, the
blood was centrifuged at 1,200 g for 10 min at room
temperature. The serum was separated out and the samples
were aliquoted and stored at −20°C until assayed.
Parasitological diagnosis
Thick blood smears were stained with 5% Giemsa solution
and examined for Plasmodium species by two microsco-
pists. Parasitaemia was assessed by counting the number
of parasites per 200 leukocytes. If nine or fewer parasites
were found, 300 additional leukocytes were counted.
Parasitaemia were expressed as parasites/μL of blood
from each individual. Patients were grouped by level of
parasitaemia (low parasitaemia up to 750 parasites/μL and
high parasitaemia above 752.5 parasites/μL) as recom-
mended by clinical procedures [21] and number of previous
episodes of malaria (Ø episode - no previous episodes
of malaria or primoinfected and > 1 episode - more than
one previous episode of malaria).
Cytokine assay
The plasma levels of the cytokine IL-10 was assessed by
enzyme-linked immunonosorbent assay (ELISA), using
pairs of cytokine-specific monoclonal antibodies provided
by commercially available assay (BD Biosciences -
Pharmingen, San Diego, CA, USA). All tests were per-
formed according to the manufacturer’s instructions. Each
plate included a standard curve of recombinant human
cytokine in parallel with the samples, the final enzyme
activity was measured by a microplate reader automatic,
V-max (Molecular Devices, Sunnyvale, USA) at 405 nm.
All samples were measured in duplicate, and the average of
the two values of optical density was used for all analyses.








Haemoglobin (g/dL) 12.6 ± 0.3** 13.8 ± 0.2
Haematocrit (%) 37.4 ± 0.9* 40.1 ± 0.7
Total WBC (103/mm3) 5561 ± 232.1*** 7520 ± 350.2
Lymphocytes (103/mm3) 1415 ± 163.9*** 2309 ± 137.4
Platelets (cells/mm3) 128.9 ± 11.6*** 285.4 ± 10.9
Parasitaemia (parasites/μL) 3255 ± 454.9 0
CD4+ cells 858.4 ± 99.9** 1355.0 ± 51.3
CD8+ cells 422.8 ± 49.2*** 742.4 ± 50.3
CD4 + CD25 + FOXP3+ cells 52.1 ± 7.4 40.7 ± 5.9
CD4/CD8 cells 2.2 ± 0.1 1.9 ± 0.1
Analysis of the population studied according to haematological
and parasitological.
*p <0.05; **p <0.01; ***p <0.001 compared to the control group. Mann-Whitney’s
U test and Student’s t.
Table 2 Circulating cytokine levels measured in the plasma
of infected individuals P. vivax and healthy controls
Cytokine Plasma concentration of cytokine (pg/mL) Mean ± SEM
Parasitaemia Controls
Low High
IL-10 650.4 ± 59.3*### 2870.0 ± 185.3*** 326.1 ± 40.1
Relation between plasma concentration of the cytokine IL-10 and the level of
parasitaemia in patients infected by P. vivax. *p <0.05; ***p <0.001 compared
to the control group; ###p <0.001 compared with high parasitaemia.
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Blood smears of patients infected with P. vivax and
healthy controls were incubated with 5% albumin bovine
in PBS (PBSA) to block nonspecific binding and perme-
abilized with Teen 20 at 0.4% in PBS, as described before
[22]. A cocktail of primary antibodies were used to identify
ANXA1 expression and lymphocyte subpopulation. Thus
a polyclonal rabbit anti-ANXA1 antibody (1/200 in 1%
PBSA) (Invitrogen, USA) and a specific lymphocyte marker:
mouse anti-CD8, anti-CD4, anti-CD25 and anti-FOXP3
(Invitrogen, USA) (1/200 in 1% PBSA) were added into the
slides and incubated overnight at 4°C. After repeated wash-
ings in 1% PBSA, a goat anti-rabbit (Fc fragment-specific)
antibody conjugated to fluorochrome ALEXAFLUOR 488®
and goat anti-mouse, conjugated to fluorochrome ALEX-
AFLUOR 546® (1/50 in 1% PBSA) and the marker DAPI
nuclei (4′,6-diamidino-2-phenylindole) were added. Ana-
lysis was conducted with a microscope AxioScopeA1 (Carl
Zeiss, GR) equipped with a DXM1200 digital camera,
using the Software AXIOVISION, version 4.8. For cell
number quantification: CD4+, CD8+ and Treg cells
(CD4+/CD25+/FOXP3+) and ANXA1 expression 100
separate fields of each individual smears were evaluated.
The protein ANXA1 expression was quantified by mean
optical density (MOD) measured by the Software Axiovi-
sion. Data was obtained from the light spectrum, with
values that range from 0 to 255 (arbitrary units – A.U.).
Statistical analysis
Data were expressed as mean ± standard error of the mean
(SEM). To compare the haematological and parasitological
data of individuals, the Mann-Whitney’s U and student’s t
test was used. To compare cytokine IL-10 levels and
ANXA1expression, data were tested using a one-way
analysis of variance (one-way ANOVA) with a Bonferroni
pos-test. For all statistical analysis, the Software GraphPad
PRISM (La Jolla, CA, USA) was used. The p value < 0.05
was considered significantly different.
Results
Study subjects
The clinical and laboratory parameters of malaria patients
and healthy controls are shown in Table 1. The haemato-
logical parameters in patients with symptomatic acute
malaria infected with P. vivax were statistically lower when
compared to healthy control individuals. As expected, T
CD4+ and T CD8+ cells were significantly lower during
acute illness (p < 0.001). However, the CD4/CD8 ratio
showed no statistical difference.
With respect to Treg cell number, the data showed no
statistical difference when compared between the malaria
patients and the control. However, evaluating these
patients according to the number of parasites and the
number of previous episodes, it was observed that patientswith low parasitaemia and who have had more than one
previous episode of malaria showed a significant increase
in these cells (96.0 ± 8.6 × 103 cells/mm3, and 81.9 ± 8.2
respectively) when compared to control individuals.
Primoinfected patients with high parasitaemia showed
no statistical difference when compared to the control
(52.6 ± 7.2 and 37.8 ± 6.8, respectively).
IL-10 plasma levels
The IL-10 levels were increased in subjects with high
parasite density (> 752.5 parasites/μl) in comparison with
those with low density (≤ 750.0 parasites/μl) (respectively
2870 ± 185.3 and 650.4 ± 59.3 pg/mL; p < 0.001) (Table 2).
Also, the IL-10 concentrations in plasma were increased
in an episode-dependent manner. In the patients with more
than one previous episode, the level were significantly
higher than in the primoinfected (respectively, 659.9 ± 49.4
and 363.9 ± 31.1 pg/mL; p <0.001) (Table 3).
Quantification of ANXA1 expression in lymphocytes
CD4+, CD8+ and Treg
The endogenous protein ANXA1 expression in circulating
lymphocytes subpopulations of patients with malaria
Table 3 Concentration of IL-10 in infected by P. vivax,





cytokine (pg/mL) Mean ± SEM
IL-10
Ø episode 363.9 ± 31.1###
> 1 episode 659.9 ± 49.4
Relation between plasma concentration of IL-10 and the number of
previous episodes of Plasmodium vivax malaria. ###p <0.001 compared
with > 1 episode.
Table 4 Expression of ANXA1 and the level of
parasitaemia in infected patients with P. vivax
Lymphocytes Intracellular expression of ANXA1
(A.U.) in T CD4+, T CD8+ and Treg Mean ± SEM
Parasitaemia Controls
Low High
CD4+ 86.7 ± 3.0*** 88.5 ± 1.9*** 108.4 ± 3.4
CD8+ 76.7 ± 2.0*** 86.3 ± 2.6*** 110.9 ± 5.5
Treg 118.1 ± 3.9***### 90.5 ± 2.6 95.3 ± 2.9
Relation between expression of endogenous ANXA1 and the level of
parasitaemia in TCD4+, TCD8+ and Treg from patients infected with
Plasmodium vivax. ***p <0.001 compared to the control group; ###p <0.001
compared with high parasitaemia.
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by immunofluorescence (Figure 1). When the patients
were classified by parasitaemia levels, a reduction in
ANXA1 expression was observed in CD4+ and CD8+ T
cells, when compared to control group (Table 4). The
ANXA1 was significantly reduced in CD4+ T cells both
groups of low (86.7 ± 3.0 A.U., p <0.001) and high para-
sitaemia (88.5 ± 1.9 A.U., p <0.001) when compared to
control group (108.4 ± 3.4 A.U.). The same was observed
in CD8+ T cells (76.7 ± 2.0, 86.3 ± 2.6 A.U., respectively
low and high parasitaemia, p <0.001). Finally, the analysis of
ANXA1 expression in Treg cells indicate an increase only
in the group of low parasitaemia (118.1 ± 3.9, p <0.001)
compared to the control group (95.3 ± 2.9 A.U.).
Also, the ANXA1 expression in lymphocytes was ana-
lysed according to the number of previous episodes of
malaria. It was found that an increase of approximately
50% in ANXA1 expression was observed in CD4+ lym-
phocytes from patients who have been exposed more
than once to the parasite (96.0 ± 2.5 A.U., p <0.001)
compared to primoinfected (50 , 3 ± 1.7 A.U.). However,
this endogenous protein had higher levels in CD8+
(108.5 ± 3.1 A.U., p <0.01) and Treg (87.5 ± 2.5 A.U.,
p <0.001) from patients primoinfected (Table 5).Figure 1 ANXA1 immunoreactivity in CD4+ of patients infected wit
expression was observed in the cytoplasm, stained with FITC-conjugated
subpopulation was done by the antibody against a specific marker and
observed. Bar = 10 μm.Discussion
Studies evaluating the mechanisms involved in Plasmodium
infection showed that the immune system develops a
potent response against the parasite causing changes in
several haematological components and mediators of
immune system [23,24]. Moreover, more than 80% of
diagnosed cases in Brazil are caused by P. vivax [25].
Several studies have reported haematological changes
in patients with malaria. In this study, a reduction in
haematocrit, haemoglobin, leukocytes and platelets was
observed during the acute phase of the disease induced
by P. vivax [26-28]. In the literature, there are two
mechanisms that can explain the lymphocytes depletion
in patients with P. falciparum and P. vivax in the acute
phase of the disease: sequestration of cells to lymph nodes
or other body parts and abnormal cell death through
apoptosis [29].
Furthermore, Braga et al. [30] demonstrated that
malaria-specific proliferative T cell responses to various
malaria antigens are commonly observed to be higher in
non-immune or semi-immune rather than in the immune
subjects, i.e., continuous exposure to malaria in areas of
low endemicity may lead to a specific decrease of the Th P. vivax. (A) The nuclei were stained with DAPI. (B) The ANXA1
secondary antibody. (C) The identification of lymphocyte
a secondary TRITC-conjugated antibody. CD4+ cells were
Table 5 Expression of ANXA1 in infected by P. vivax,
according to the number of previous episodes of malaria
Number of previous episodes
of malaria
Intracellular expression
of ANXA1 (U.A.) Mean ± SEM
CD4+ CD8+ Treg






> 1 episode 96.0 ± 2.5 83.5 ± 2.1 65.5 ± 1.7
Relation between intracellular expression of ANXA1 in lymphocytes and the
number of previous episodes of Plasmodium vivax malaria. ###p <0.001compared
with > 1 episode.
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number of CD4+ and CD8+ T cells were significantly
lower during acute malaria.
There is a well-recognized but unmet need for improved
diagnostics based on biological markers to characterize
disease status, parasitaemia and clinical outcome. There-
fore, the evaluation of IL-10 and ANXA1 in the individuals
with malaria was performed. Plasma levels of IL-10 were
elevated in patients with high parasitaemia and who have
had more than one episode of malaria. This result shows
that re-exposure to P. vivax may induce IL-10 production.
High levels of IL-10 were also detected in African and In-
dian children with anaemia and high levels of parasitaemia
[33,34]. Other studies also showed a positive relationship
between the levels of IL-10 and parasite density in individ-
uals infected with P. vivax [35]. IL-10 plays an important
role in immunoregulation, inhibiting Th1 function and
promoting the activity of NK cells [35-40]. Other studies
indicate that IL-10 were associated with Th2 response
during malaria [41]. The results obtained in this work
together with previous literature findings, emphasize
that IL-10 may regulate the proinflammatory response,
participates in parasite elimination and contributes to
the pathogenesis of the disease.
The expression of ANXA1 in subpopulations of T lym-
phocytes CD4+, CD8+ and Treg were assessed. ANXA1
is known to be constitutively expressed on leukocytes
and epithelial cells [17,18,42,43]. Depending on the cell
stimulus, ANXA1 expression may be increased endogen-
ously in order to regulate the inflammatory processes
[18,44]. In this work, lymphocytes sub-populations were
observed to expressed ANXA1. This data is in agreement
with findings in the literature, which indicates a pleiotropic
mechanism of action of this protein in the innate and
adaptive immune system [18,19,45,46].
Some studies suggest that ANXA1 demonstrated an
antiproliferative activity in lymphocytes [17,19,44,47]. It
was demonstrated a reduction in ANXA1 expression in
CD4+ and CD8+ T cells. It was also observed a positive
relation between ANXA1 expression and the number of
previous episodes of malaria in CD4+ T cells. These data
might indicate that ANXA1 could regulate the numberof this cell population. This is the first time a paper
analyses the expression of ANXA1 in infection by this
parasite.
With respect to Treg lymphocytes, the number of
these cells and the ANXA1 expression were increased
in patients with low parasitaemia. There are no data on
the literature about the ANXA1 functionality in Treg
cells. These results are interesting and may indicate that
this protein can function differently in each lymphocytes
subpopulation.
Also, it is important to highlight that high ANXA1
expression in some lymphocytes and other leukocytes
might had influence on the levels of IL-10 in malaria
patients. Some studies described that ANXA1 can induce
the IL-10 production [20,47,48] through activation of ERK
cascade [49]. This cytokine can be produced by several
cell types, such as lymphocytes Treg [44], CD8+ lympho-
cytes and monocytes [50].Conclusion
In conclusion, this study evidenced that in patients infected
with P. vivax the release of immunoregulatory molecules
can be influenced by the level of parasitaemia and the
number of previous episodes of malaria. ANXA1 is ex-
pressed differently in lymphocyte sub-populations and
may have a role in regulating lymphocyte proliferation.
Furthermore, ANXA1 may be contributing to IL-10 pro-
duction in plasma of patients with vivax malaria.Competing interests
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